EVERESTO.BO Everest Organics BSE down 16.57% pre-market 17 Feb: watch volume

EVERESTO.BO stock opened as a clear pre-market top loser on 17 Feb 2026 after an intraday drop to INR 332.35, down 66.00 or -16.57% from the previous close. Volume has surged to 66,022.00, nearly 24.00 times average, flagging heavy selling interest. Traders on the BSE are watching liquidity and valuation signals as the Healthcare peer group trades at different multiples.

Price action and key metrics for EVERESTO.BO stock

Everest Organics (EVERESTO.BO) fell to INR 332.35 pre-market on 17 Feb 2026. The stock opened at INR 378.05 and traded intraday between INR 318.95 and INR 386.20. Market cap stands at INR 3,227,293,316.00 with 9,710,526.00 shares outstanding. EPS is 6.37 and reported PE is 52.17, signaling a premium to some healthcare peers.

Valuation and sector comparison for EVERESTO.BO stock

EVERESTO.BO’s PE near 52.17 compares to the Healthcare sector average PE of about 39.22, showing a valuation gap. Price to book is 4.45 and EV/EBITDA is 20.55. Receivables days are long at 224.37 and the current ratio is 1.08, indicating working capital stretch versus peers. These metrics help explain investor caution after the sharp drop.

Technical picture and trading signals for EVERESTO.BO stock

Technicals show mixed momentum: RSI 56.64 and MACD histogram -0.09. The 50-day average is INR 450.62 and the 200-day average is INR 405.01, both above the current price. On-balance volume turned negative even as MFI hit 84.90. The stock is oversold on price but faces resistance near the INR 442.68 Bollinger lower band.

Meyka AI grade and analyst context for EVERESTO.BO stock

Meyka AI rates EVERESTO.BO with a score of 68.34 out of 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Independent company rating data also shows a company rating of C with a Sell recommendation on 16 Feb 2026, reflecting mixed signals on leverage and margins.

Forecasts, price targets and model outlook for EVERESTO.BO stock

Meyka AI’s forecast model projects a monthly level of INR 379.28 and a yearly level of INR 293.75. Versus the current price INR 332.35, the monthly projection implies an upside of +14.12%, while the yearly projection implies a downside of -11.61%. Forecasts are model-based projections and not guarantees, and they should be weighed with liquidity and sector trends.

Catalysts, risks and what to watch in pre-market for EVERESTO.BO stock

Watch volume spikes, receivables updates, and any corporate news from Everest Organics on the BSE. Key risks include stretched receivables, leverage metrics like debt/equity 0.68, and thin operating cash flow. Potential catalysts would be improved collection cycles, export orders, or margin expansion news. See the company site for filings source and BSE updates source.

Final Thoughts

EVERESTO.BO stock is the top pre-market loser on 17 Feb 2026 after a sharp intraday decline to INR 332.35 on heavy volume 66,022.00. Valuation metrics such as PE 52.17 and P/B 4.45 sit above many healthcare peers, amplifying downside risk after poor short-term flows. Meyka AI’s forecast model projects INR 379.28 for the next month, implying a potential +14.12% upside from the current price, while the yearly model at INR 293.75 implies -11.61% downside. Traders should treat these model outputs as probabilistic signals, not guarantees. Given the mixed technicals, stretched receivables, and the company’s current ratio near 1.08, market participants should wait for clearer liquidity improvement or confirmatory news before increasing exposure. Meyka AI provides this AI-powered market analysis to help frame the risk-reward profile, but investors must do their own due diligence and check official BSE filings before acting.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.